Dermatology

HomeAbout UsFacultyLaurence J. Meyer, M.D., Ph.D.

Laurence J. Meyer, M.D., Ph.D.

Laurence J. Meyer, M.D., Ph.D.

Professor of Dermatology and Internal Medicine,
Associate Chief of Staff, Research, SLC VAMC

  • B.A., 1972, University of California at San Diego
  • Ph.D., 1980, University of California at Davis
  • M.D., 1982, University of Miami, Florida
  • Residency in Internal Medicine, 1982-1985, University of Utah
  • Residency in Dermatology, 1992-1995, University of Utah
  • Fellowship in Clinical Genetics, University of Utah
  • Fellowship in Geriatric Medicine, University of Utah
  • Board Certifications in Internal Medicine, Dermatology, Clinical Genetics and Geriatrics

Clinical and Research Interests

  • Clinical interests include genetic dermatology especially including the genetic predisposition to melanoma, and geriatric dermatology.
  • Research interests include melanoma genetics. At least 10% of melanoma is estimated to be due to a specific genetic risk factor. Some portion of this is due to mutations in p16. In many cases an abnormal number and pattern of nevi are associated with this increased melanoma risk. Genetic pathways that are activated in nevi may give a clue to other inherited melanoma risk genes. Another area of research includes the immunobullous diseases that are more common in the elderly.
  • Dr. Meyer's outpatient clinics are restricted to the VA hospital.

Selected Publications

  • Jaskowski TD, Hamblin T, Wilson AR, Hill HR, Book LS, Meyer LJ, Zone JJ, Hull CM. IgA Anti-Epidermal Transglutaminase Antibodies in Dermatitis Herpetiformis and Pediatric Celiac Disease. J Invest Dermatol. 2009; (Epub ahead of print).
  • Florell SR, Meyer LJ, Boucher KM, Grossman D, Cannon-Albright LA, Harris RM, Samlowski WE, Zone JJ, Leachman SA. Increased Melanocytic Nevi and NEvus Density in a G-34T CDKN2A/p16 Melanoma-Prone Pedigree. J Invest Dermatol. 2008; 128(8), 2122-2125.
  • Hull CM, Liddle M, Hansen N, Meyer LJ, Schmidt L, Taylor T, Jaskowski TD, Hill HR, Zone JJ. Elevation of IgA anti-epidermal transglutaminase antibodies in dermatitis herpetiformis. Br J Dermatol. 2008: 159(1), 120-4.
  • Pershing LK, Tirumala VP, Nelson JL, Corlett JL, Lin AG, Meyer LJ, Leachman SA. Reflectance spectrophotometer: the dermatologists' sphygmomanometer for skin phototyping? J Invest Dermatol. 2008: 128(7), 1633-40.
  • Zone, J.J., T. Taylor, C. Hull, L.A. Schmidt, L.J. Meyer, IgE basement membrane zone antibodies induce eosinophil infiltration and blisters in engrafted human skin on SCID mice. J Invest Dermatol 127: 1167-1174, 2007.
  • Donaldson, M.R., J.J. Zone, L.A. Schmidt, T.B. Taylor, S.L. Neuhausen, C.M. Hull, L.J. Meyer, Epidermal transglutaminase deposits in perilesional and uninvolved skin in patients with dermatitis herpetiformis. J Invest Dermatol, in press, electronically published, 2007.
  • Zone, J.J., C.A. Egan, T.B. Taylor, and L.J. Meyer, IgA autoimmune disorders: development of a passive transfer mouse model. J Investig Dermatol Symp Proc, 2004. 9(1): p. 47-51.
  • Meyer LJ, Piepkorn MW , Goldgar DE, Lewis CM, Cannon-Albright LA, Zone JJ, Skolnick MH. Interobserver concordance in discriminating clinical atypia of melanocytic nevi, and correlations with histologic atypia. J Am Acad Dermatol 1996;34:618-25
  • Meyer LJ, Schmidt LA, Goldgar DE, Piepkorn MW. Survival and histopathologic characteristics of human melanocytic nevi transplanted to athymic (nude) mice. Am J Dermatopathol 1995;17:368-373
  • Cannon-Albright LA, Meyer LJ, Goldgar DE, Lewis CM, McWhorter WP, Jost M, Harrison D, Anderson DE, Zone JJ, Skolnick MH. Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus (MLM). Cancer Res 1994;54:6041-44
  • Meyer, LJ. Drug therapy for neurofibromatosis. Arch Dermatol 1993;129:625-626